U.S. Pharma Industry Analysis
UpdatedApr 25, 2024
DataAggregated Company Financials
Companies282
- 7D0.08%
- 3M3.2%
- 1Y13.2%
- YTD4.8%
Over the last 7 days, the Pharma industry has remained flat. The past year has been better, since the industry has gained 14% in that time. Looking forward, earnings are forecast to grow by 21% annually.
Industry Valuation and Performance
Has the U.S. Pharma Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Thu, 25 Apr 2024 | US$1.8t | US$357.7b | US$29.8b | 20.4x | 60.9x | 5.1x |
| Sat, 23 Mar 2024 | US$1.9t | US$355.3b | US$22.6b | 19.8x | 82.6x | 5.3x |
| Mon, 19 Feb 2024 | US$1.9t | US$355.0b | US$23.9b | 28.3x | 79.6x | 5.4x |
| Wed, 17 Jan 2024 | US$1.8t | US$375.2b | US$33.9b | 27.6x | 52.6x | 4.7x |
| Fri, 15 Dec 2023 | US$1.7t | US$375.1b | US$33.9b | 27x | 49.6x | 4.5x |
| Sun, 12 Nov 2023 | US$1.6t | US$375.5b | US$34.1b | 26.5x | 47.6x | 4.3x |
| Tue, 10 Oct 2023 | US$1.7t | US$381.8b | US$43.8b | 18.5x | 38.4x | 4.4x |
| Thu, 07 Sep 2023 | US$1.7t | US$381.8b | US$43.9b | 19.2x | 38.8x | 4.5x |
| Sat, 05 Aug 2023 | US$1.7t | US$379.3b | US$43.5b | 21.5x | 38.7x | 4.4x |
| Mon, 03 Jul 2023 | US$1.8t | US$392.8b | US$60.2b | 18.7x | 29.2x | 4.5x |
| Wed, 31 May 2023 | US$1.7t | US$393.0b | US$60.6b | 17.8x | 27.4x | 4.2x |
| Fri, 28 Apr 2023 | US$1.7t | US$402.7b | US$63.2b | 17.1x | 26.1x | 4.1x |
| Sun, 26 Mar 2023 | US$1.6t | US$401.2b | US$69.4b | 14.7x | 22.4x | 3.9x |
| Tue, 21 Feb 2023 | US$1.6t | US$401.8b | US$68.4b | 18.8x | 23.9x | 4.1x |
| Thu, 19 Jan 2023 | US$1.7t | US$403.7b | US$70.6b | 17.6x | 23.9x | 4.2x |
| Sat, 17 Dec 2022 | US$1.7t | US$403.7b | US$70.7b | 16.7x | 24.6x | 4.3x |
| Mon, 14 Nov 2022 | US$1.7t | US$403.6b | US$71.1b | 12.9x | 23.6x | 4.2x |
| Wed, 12 Oct 2022 | US$1.6t | US$403.0b | US$71.3b | 12.4x | 21.9x | 3.9x |
| Fri, 09 Sep 2022 | US$1.6t | US$403.0b | US$71.3b | 13.7x | 22.3x | 4x |
| Sun, 07 Aug 2022 | US$1.6t | US$403.3b | US$69.5b | 19.3x | 23.5x | 4.1x |
| Tue, 05 Jul 2022 | US$1.7t | US$392.4b | US$65.1b | 21.9x | 26x | 4.3x |
| Thu, 02 Jun 2022 | US$1.7t | US$392.5b | US$64.8b | 21.5x | 25.7x | 4.2x |
| Sat, 30 Apr 2022 | US$1.6t | US$380.0b | US$61.3b | 20.5x | 26.8x | 4.3x |
| Mon, 28 Mar 2022 | US$1.6t | US$373.8b | US$60.3b | 22.3x | 27.3x | 4.4x |
| Wed, 23 Feb 2022 | US$1.5t | US$373.4b | US$59.2b | 21x | 25.4x | 4x |
| Fri, 21 Jan 2022 | US$1.6t | US$361.3b | US$37.7b | 23.3x | 41.8x | 4.4x |
| Sun, 19 Dec 2021 | US$1.6t | US$361.1b | US$38.1b | 22.6x | 42.9x | 4.5x |
| Tue, 16 Nov 2021 | US$1.6t | US$360.6b | US$38.5b | 24.1x | 41.4x | 4.4x |
| Thu, 14 Oct 2021 | US$1.5t | US$337.7b | US$24.8b | 21.5x | 59.7x | 4.4x |
| Sat, 11 Sep 2021 | US$1.5t | US$338.7b | US$25.4b | 18.4x | 60.1x | 4.5x |
| Mon, 09 Aug 2021 | US$1.6t | US$338.5b | US$25.8b | 20.9x | 61.2x | 4.7x |
| Sun, 02 May 2021 | US$1.4t | US$315.6b | US$19.6b | 18.8x | 71.9x | 4.5x |
Price to Earnings Ratio
71.9x
Current Industry PE
- Investors are optimistic on the American Pharmaceuticals industry, and appear confident in long term growth rates.
- The industry is trading at a PE ratio of 60.9x which is higher than its 3-year average PE of 41.1x.
- The 3-year average PS ratio of 4.4x is lower than the industry's current PS ratio of 5.1x.
Past Earnings Growth
- The earnings for companies in the Pharmaceuticals industry have grown 15% per year over the last three years.
- Revenues for these companies have grown 4.3% per year.
- This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.
Industry Trends
Which industries have driven the changes within the U.S. Healthcare industry?
| US Market | 1.21% | |
| Healthcare | 1.41% | |
| Pharma | 0.083% | |
| Pharma | 0.083% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| JNJ Johnson & Johnson | US$148.53 | 2.6% +US$9.1b | -8.7% | PE18.7x | |
| PFE Pfizer | US$26.27 | 3.3% +US$4.8b | -32.0% | PE69.7x | |
| MRK Merck | US$127.00 | 1.3% +US$4.1b | 12.0% | PE881.4x | |
| BMY Bristol-Myers Squibb | US$48.86 | 2.1% +US$2.1b | -28.2% | PE12.3x | |
| VTRS Viatris | US$11.55 | 4.1% +US$534.4m | 26.9% | PE250.8x |
